Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, is currently under FDA review.

Astellas is currently pitching peak sales guidance of 300 billion yen ($2.2 billion) to 500 billion yen per year for Veozah, which could go a long way to ease the pain of patent losses to its ...

New phase 3 data sets up filings for Bayer's non-hormonal menopause symptom treatment elinzanetant and a challenge to Astellas’ first-to-market Veozah ...

There’s also the issue of accessibility and cost—veozah has a monthly cost of roughly $550, while hypnosis can be accessed through an evidence-based digital therapeutic app created in ...

Lindsey Bever is a reporter for The Washington Post's Well+Being desk, covering women's health, mental health and medical myths, among other issues. She was previously a reporter at the Dallas ...

Hypovolemia Pathophysiology. Normally, your body is made of about 50%-60% fluid, including water, blood, and lymphatic fluid. When your fluid levels are out of balance (too high or too low ...

Arterial stiffness is a growing epidemic associated with increased risk of cardiovascular events, dementia, and death. Decreased compliance of the central vasculature alters arterial pressure and flow ...

The mechanisms underlying the progression of diabetes mellitus and heart failure are closely intertwined, such that worsening of one condition is frequently accompanied by worsening of the other; the ...

Vasomotor symptoms include hot flashes and disrupted sleep, and are typically associated with menopause. However, these symptoms can occur in almost 90% of women with early breast cancer who are ...

Veozah is the first drug of its kind—a neurokinin 3 (NK3) receptor antagonist—and it works by binding and blocking a receptor in the brain that regulates body temperature. Its high price tag, around ...